ZVIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zevia PBC (ZVIA) is not a strong buy at the moment for a long-term beginner investor. The stock is facing bearish technical indicators, insider selling, and mixed financial performance. While there are some positive catalysts like cost control improvements and new product launches, the lack of strong growth and analyst downgrades suggest a cautious approach. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in ZVIA is recommended until there are clearer signs of recovery or growth.
The technical indicators for ZVIA are bearish. The MACD is negative and expanding downward, the RSI is neutral at 21.698, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (S1: 1.237, S2: 1.098), with no immediate signs of a reversal.
Improved cost control as reflected in reduced net loss and adjusted EBITDA.
Plans for market expansion and new product launches in
Strengthened governance with new board appointments.
Insider selling has increased significantly by 1223.80% in the last month.
Mixed Q4 results with a 4% decline in sales and a YoY drop in revenue, net income, and EPS.
Analysts have lowered price targets, indicating skepticism about near-term performance.
Bearish technical indicators and lack of strong trading trends.
In Q4 2025, Zevia's revenue dropped by 4.03% YoY to $37.87 million. Net income fell by 77.25% YoY to -$1.31 million, and EPS declined by 80% YoY to -$0.02. Gross margin also decreased by 2.5% YoY to 47.27%. While cost control measures have improved adjusted EBITDA, overall financial performance remains weak.
Analysts have mixed views but are generally cautious. Morgan Stanley lowered its price target to $1.75 from $2.90 with an Equal Weight rating. Telsey Advisory reduced its target to $5 from $6 but maintains an Outperform rating, citing progress in the company's turnaround. Goldman Sachs lowered its target to $3 from $3.50, keeping a Neutral rating. These downgrades reflect concerns about near-term performance despite some optimism about long-term growth.
